Photodynamic therapy (PDT) is a noninvasive treatment that utilizes light treatment along with application of a photosensitizing agent. In dermatology, PDT is commonly used and approved for the treatment of oncological conditions such as actinic keratosis, Bowen disease and superficial basal cell carcinoma. In the last 2 decades however, PDT has also been used for the treatment of several nonneoplastic dermatological diseases. The present review summarizes published data on PDT application in skin appendage disorders. Our literature review shows that: (a) PDT may be a suitable treatment for acne, folliculitis decalvans, hidradenitis suppurativa, nail diseases, and sebaceous hyperplasia; (b) there is a lack of agreement on PDT features (type, concentrations and incubation period of used substances, number and frequency of PDT sessions, optimal parameters of light sources, and patient characteristics [e.g., failure to previous treatments, disease severity, body surface area involved, etc.] which should guide PDT use in these diseases); (c) further research is needed to establish international guidelines helping dermatologists to choose PDT for the right patient at the right time.

Keywords:
Photodynamic therapy, Hidradenitis suppurativa, Acne, Sebaceous hyperplasia, Onychomycosis
1.
Calzavara-Pinton PG, Rossi MT, Aronson E, Sala R; Italian Group for Photodynamic Therapy: A retrospective analysis of real-life practice of off-label photodynamic therapy using methyl aminolevulinate (MAL-PDT) in 20 Italian dermatology departments. 1. Inflammatory and aesthetic indications. Photochem Photobiol Sci 2013;12:148-157.
2.
Wan MT, Lin JY: Current evidence and applications of photodynamic therapy in dermatology. Clin Cosmet Investig Dermatol 2014;7:145-163.
3.
Rkein AM, Ozog DM: Photodynamic therapy. Dermatol Clin 2014;32:415-425.
4.
Raab O: Uber die Wirkung fluoreszierender Stoffe auf Infusorien. Z Biol 1900;39:524-546.
5.
Von Tappeiner H: Uber die Wirkung fluoreszierender Stoffe auf Infusorien nach Versuchen von O. Raab. Muench Med Wochenschr 1900;47:5.
6.
Von Tappeiner H, Jesionek A: Therapeutische Versuche mit fluoreszierenden Stoffen. Muench Med Wochenschr 1903;47:2042-2044.
7.
Ackroyd R, Kelty C, Brown N, Reed: The history of photodetection and photodynamic therapy. Photochem Photobiol 2001;74:656-669.
8.
Dougherty TJ: Photoradiation therapy for the treatment of malignant tumours. Cancer Res 1978;36:2628-2635.
9.
Gold MH: Therapeutic and aesthetic uses of photodynamic therapy part five of a five-part series: ALA-PDT and MAL-PDT what makes them different. J Clin Aesthet Dermatol 2009;2:44-47.
10.
Fonda-Pascual P, Moreno-Arrones OM, Alegre-Sanchez A, Saceda-Corralo D, Buendia-Castaño D, Pindado-Ortega C, Fernandez-Gonzalez P, Velazquez-Kennedy K, Calvo-Sánchez MI, Harto-Castaño A, Perez-Garcia B, Bagazgoitia L, Vaño-Galvan S, Espada J, Jaen-Olasolo P: In situ production of ROS in the skin by photodynamic therapy as a powerful tool in clinical dermatology. Methods 2016;109:190-202.
11.
Morton C, Szeimies RM, Sidoroff A, Wennberg AM, Basset-Seguin N, Calzavara-Pinton P, Gilaberte Y, Hofbauer G, Hunger R, Karrer S, Lehmann P, Piaserico S, Ulrich C, Braathen L; European Dermatology Forum: European Dermatology Forum Guidelines on topical photodynamic therapy. Eur J Dermatol 2015;25:296-311.
12.
Ortel B, Shea CR, Calzavara-Pinton PG: Molecular mechanisms of photodynamic therapy. Front Biosci 2009;14:4157-4172.
13.
Ramos-e-Silva M, Carneiro SC: Acne vulgaris: review and guidelines. Dermatol Nurs 2009;21:63-68.
14.
Baldwin HE: The interaction between acne vulgaris and the psyche. Cutis 2002;70:133-139.
15.
Eichenfield LF, Del Rosso JQ, Mancini AJ, Cook-Bolden F, Stein Gold L, Desai S, Weiss J, Pariser D, Zeichner J, Bhatia N, Kircik L: Evolving perspectives on the etiology and pathogenesis of acne vulgaris. J Drugs Dermatol 2015;14:263-272.
16.
Divaris DX, Kennedy JC, Pottier RH: Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin IX fluorescence. Am J Pathol 1990;136:891-897.
17.
Kennedy JC, Pottier RH: Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992;14:275-292.
18.
Hongcharu W, Taylor CR, Chang Y, Aghassi D, Suthamjariya K, Anderson RR: Topical ALA-photodynamic therapy for the treatment of acne vulgaris. J Invest Dermatol 2000;115:183-192.
19.
Ramstad S, Futsaether CM, Johnsson A: Porphyrin sensitization and intracellular calcium changes in the prokaryote Propionibacterium acnes. J Photochem Photobiol B 1997;40:141-148.
20.
Itoh Y, Ninomiya Y, Tajima S, Ishibashi A: Photodynamic therapy for acne vulgaris with topical 5-aminolevulinic acid. Arch Dermatol 2000;136:1093-1095.
21.
Itoh Y, Ninomiya Y, Tajima S, Ishibashi A: Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. Br J Dermatol 2001;144:575-579.
22.
Sakamoto FH, Lopes JD, Anderson RR: Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice. I. Acne vulgaris: when and why consider photodynamic therapy? J Am Acad Dermatol 2010;63:183-193.
23.
Wiegell SR, Wulf HC: Photodynamic therapy of acne vulgaris using methyl aminolaevulinate: a blinded, randomized, controlled trial. Br J Dermatol 2006;154:969-976.
24.
Wiegell SR, Wulf HC: Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate. J Am Acad Dermatol 2006;54:647-651.
25.
Horfelt C, Funk J, Frohm-Nilsson M, Wiegleb Edstrom D, Wennberg AM: Topical methyl aminolaevulinate photodynamic therapy for treatment of facial acne vulgaris: results of a randomized, controlled study. Br J Dermatol 2006;155:608-613.
26.
Kimura M, Itoh Y, Tokuoka Y, Kawashima N: Delta-amino-levulinic acid-based photodynamic therapy for acne on the body. J Dermatol 2004;31:956-960.
27.
Gold MH, Bradshaw VL, Boring MM, Bridges TM, Biron JA, Carter LN: The use of a novel intense pulsed light and heat source and ALA-PDT in the treatment of moderate to severe inflammatory acne vulgaris. J Drugs Dermatol 2004;3:S15-S19.
28.
Taub AF: Photodynamic therapy for the treatment of acne: a pilot study. J Drugs Dermatol 2004;3:S10-S14.
29.
Alexiades-Armenakas M: Long-pulsed dye laser-mediated photodynamic therapy combined with topical therapy for mild to severe comedonal, inflammatory, or cystic acne. J Drugs Dermatol 2006;5:45-55.
30.
Santos MA, Belo VG, Santos G: Effectiveness of photodynamic therapy with topical 5-aminolevulinic acid and intense pulsed light versus intense pulsed light alone in the treatment of acne vulgaris: comparative study. Dermatol Surg 2005;31:910-915.
31.
Rojanamatin J, Choawawanich P: Treatment of inflammatory facial acne vulgaris with intense pulsed light and short contact of topical 5-aminolevulinic acid: a pilot study. Dermatol Surg 2006;32:991-996.
32.
Yeung CK, Shek SY, Bjerring P, Yu CS, Kono T, Chan HH: A comparative study of intense pulsed light alone and its combination with photodynamic therapy for the treatment of facial acne in Asian skin. Lasers Surg Med 2007;39:1-6.
33.
Kennedy JC, Pottier RH, Pross DC: Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990;6:143-148.
34.
Pollock B, Turner D, Stringer MR, Bojar RA, Goulden V, Stables GI, Cunliffe WJ: Topical aminolaevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol 2004;151:616-622.
35.
Hong SB, Lee MH: Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris. Photodermatol Photoimmunol Photomed 2005;21:322-325.
36.
Akaraphanth R, Kanjanawanitchkul W, Gritiyarangsan P: Efficacy of ALA-PDT vs. blue light in the treatment of acne. Photodermatol Photoimmunol Photomed 2007;23:186-190.
37.
Chen X, Song H, Chen S, Zhang J, Niu G, Liu X: Clinical efficacy of 5-aminolevulinic acid photodynamic therapy in the treatment of moderate to severe facial acne vulgaris. Exp Ther Med 2015;10:1194-1198.
38.
Yew YW, Lai YC, Lim YL, Chong WS, Theng C: Photodynamic therapy with topical 5% 5-aminolevulinic acid for the treatment of truncal acne in Asian Patients. J Drugs Dermatol 2016;15:727-732.
39.
Tao SQ, Li F, Cao L, Xia RS, Fan H, Fan Y, Sun H, Jing C, Yang LJ: Low-dose topical 5-aminolevulinic acid photodynamic therapy in the treatment of different severity of acne vulgaris. Cell Biochem Biophys 2015;73:701-706.
40.
Asayama-Kosaka S, Akilov OE, Kawana S: Photodynamic therapy with 5% δ-aminolevulinic acid is safe and effective treatment of acne vulgaris in Japanese patients. Laser Ther 2014;23:115-120.
41.
Yang GL, Zhao M, Wang JM, He CF, Luo Y, Liu HY, Gao J, Long CQ, Bai JR: Short-term clinical effects of photodynamic therapy with topical 5-aminolevulinic acid for facial acne conglobata: an open, prospective, parallel-arm trial. Photodermatol Photoimmunol Photomed 2013;29:233-238.
42.
Fabbrocini G, Cacciapuoti S, De Vita V, Fardella N, Pastore F, Monfrecola G: The effect of aminolevulinic acid photodynamic therapy on microcomedones and macrocomedones. Dermatology 2009;219:322-328.
43.
Sitnik TM, Hampton JA, Henderson BW: Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Br J Cancer 1998;77:1386-1394.
44.
Soukos NS, Ximenez-Fyvie LA, Hamblin MR, Socransky SS, Hasan T: Targeted antimicrobial photochemotherapy. Antimicrob Agents Chemother 1998;42:2595-2601.
45.
Hamblin MR, Hasan T: Photodynamic therapy: a new antimicrobial approach to infectious disease? Photochem Photobiol Sci 2004;3:436-450.
46.
Horfelt C, Stenquist B, Larko O, Faergemann J, Wennberg AM: Photodynamic therapy for acne vulgaris: a pilot study of the dose-response and mechanism of action. Acta Derm Venereol 2007;87:325-329.
47.
Yung A, Stables GI, Fernandez C, Williams J, Bojar RA, Goulden V: Microbiological effect of photodynamic therapy (PDT) in healthy volunteers: a comparative study using methyl aminolaevulinate and hexyl aminolaevulinate cream. Clin Exp Dermatol 2007;32:716-721.
48.
Orringer JS, Hammerberg C, Hamilton T, Johnson TM, Kang S, Sachs DL, Fisher G, Voorhees JJ: Molecular effects of photodynamic therapy or photoaging. Arch Dermatol 2008;144:1296-1302.
49.
Sakamoto FH, Torezan L, Anderson RR: Photodynamic therapy for acne vulgaris: a critical review from basics to clinical practice. II. Understanding parameters for acne treatment with photodynamic therapy. J Am Acad Dermatol 2010;63:195-211.
50.
Keyal U, Bhatta AK, Wang XL: Photodynamic therapy for the treatment of different severity of acne: a systematic review. Photodiagnosis Photodyn Ther 2016;14:191-199.
51.
IngramJR, Woo PN, Chua SL, Ormerod AD, Desai N, Kai AC, Hood K, Burton T, Kerdel F, Garner SE, Piguet V: Interventions for hidradenitis suppurativa. Cochrane Database Syst Rev 2015;10:CD010081.
52.
Megna M, Bettoli V, Chimenti S, Chiricozzi A, Naldi L, Virgili A, Girolomoni G, Monfrecola G: Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF-α agents. G Ital Dermatol Venereol 2015;150:731-739.
53.
Rambhatla PV, Lim HW, Hamzavi I: A systematic review of treatments for hidradenitis suppurativa. Arch Dermatol 2012;148:439-446.
54.
Clemmensen OJ: Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983;22:325-328.
55.
Jemec GBE, Wendelboe P: Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998;39:971-974.
56.
Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, Pouget F, Viallette C, Wolkenstein P, Bastuji-Garin S: Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatology 2009;219:148-154.
57.
Mendonca CO, Griffiths CE: Clindamycin and rifampicin combination therapy for hidradenitis suppurativa. Br J Dermatol 2006;154:977-978.
58.
van der Zee HH, Boer J, Prens EP, Jemev JB: The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009;219:143-147.
59.
Bettoli V, Zauli S, Borghi A, Toni G, Minghetti S, Ricci M, Virgili A: Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa: a prospective study on 23 patients. J Eur Acad Dermatol Venereol 2014;28:125-126.
60.
Meixner D, Schneider S, Krause M, Sterry W: Acne inversa. J Dtsch Dermatol Ges 2008;6:189-196.
61.
Boer J, Nazary M: Long-term results of acitretin therapy for hidradenitis suppurativa. Is acne inversa also a misnomer? Br J Dermatol 2011;164:170-175.
62.
Matusiak L, Bieniek A, Szepietowski JC: Acitretin in hidradenitis suppurativa treatment - own experiences. Przegl Dermatol 2012;99:356-357.
63.
Chow ET, Mortimer PS: Successful treatment of hidradenitis suppurativa and retroauricular acne with etretinate. Br J Dermatol 1992;126:415.
64.
Scheinfeld N: The use of photodynamic therapy to treat hidradenitis suppurativa a review and critical analysis. Dermatol Online J 2015;21.
65.
Zeina B, Greenman J, Corry D, Purcell WM: Antimicrobial photodynamic therapy: assessment of genotoxic effects on keratinocytes in vitro. Br J Dermatol 2003;148:229-232.
66.
Sharma M, Visai L, Bragheri F, Cristiani I, Gupta PK, Speziale P: Toluidine blue-mediated photodynamic effects on staphylococcal bio-films. Antimicrob Agents Chemother 2008;52:299-305.
67.
Fadel MA, Tawfik AA: New topical photodynamic therapy for treatment of hidradenitis suppurativa using methylene blue niosomal gel: a single-blind, randomized, comparative study. Clin Exp Dermatol 2015;40:116-122.
68.
Nisnevitch M, Nakonechny F, Nitzan Y: Photodynamic antimicrobial chemotherapy by liposome-encapsulated water-soluble photosensitizers. Bioorg Khim 2010;36:396-402.
69.
Sbarra MS, Arciola CR, Di Poto A, Saino E, Rohde H, Speziale P, Visai L: The photodynamic effect of tetra-substituted Nmethyl-pyridyl-porphine combined with the action of vancomycin or host defense mechanisms disrupts Staphylococcus epidermidis bio-films. Int J Artif Organs 2009;32:574-83.
70.
Andino Navarrete R, Hasson Nisis A, Parra Cares J: Effectiveness of 5-aminolevulinic acid photodynamic therapy in the treatment of hidradenitis suppurativa: a report of 5 cases. Actas Dermosifiliogr 2014;105:614-617.
71.
Schweiger ES, Riddle CC, Aires DJ: Treatment of hidradenitis suppurativa by photodynamic therapy with aminolevulinic acid: preliminary results. J Drugs Dermatol 2011;10:381-386.
72.
Saraceno R, Teoli M, Casciello C, Chimenti S: Methyl aminolaevulinate photodynamic therapy for the treatment of hidradenitis suppurativa and pilonidal cysts. Photodermatol Photoimmunol Photomed 2009;25:164-165.
73.
Fabbrocini G, Cacciapuoti S, Capasso C, Monfrecola G: Photodynamic therapy: a treatment tool for hidradenitis suppurativa. J Plast Dermatol 2011;7:241-246.
74.
Rodríguez-Prieto MÁ, Valladares-Narganes LM, González-Sixto B, Noguerol-Cal M: Efficacy of intralesional photodynamic therapy for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2013;68:873-875.
75.
Valladares-Narganes LM, Rodríguez-Prieto MA, Blanco-Suárez MD, Rodriguez-Lage C, García-Doval I: Treatment of hidradenitis suppurativa with intralesional photodynamic therapy using a laser diode attached to an optical cable: a promising new approach. Br J Dermatol 2015;172:1136-1139.
76.
Agut-Busquet E, Romaní J, Gilaberte Y, García-Malinis A, Ribera-Pibernat M, Luelmo J: Photodynamic therapy with intralesional methylene blue and a 635 nm light-emitting diode lamp in hidradenitis suppurativa: a retrospective follow-up study in 7 patients and a review of the literature. Photochem Photobiol Sci 2016;15:1020-1028.
77.
Simmons BJ, Griffith RD, Falto-Aizpurua LA, Nouri K: An update on photodynamic therapies in the treatment of onychomycosis. J Eur Acad Dermatol Venereol 2015;29:1275-1279.
78.
Salomon J, Szepietowski JC, Proniewick A: Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003;7:317-321.
79.
Fernández-Guarino M, Harto A, Sánchez-Ronco M, García-Morales I, Jaén P: Pulsed dye laser vs. photodynamic therapy in the treatment of refractory nail psoriasis: a comparative pilot study. J Eur Acad Dermatol Venereol 2009;23:891-895.
80.
Aspiroz C, Fortuno Cebamanos B, Rezusta A, Paz-Cristóbal P, Domínguez-Luzón F, Gené Díaz J, Gilaberte Y: Photodynamic therapy for onychomycosis: case report and review of the literature. Rev Iberoam Micol 2011;28:191-193.
81.
De Berker D: Diagnosis and management of nail psoriasis. Dermatol Ther 2002;15:165-172.
82.
Tan ES, Chong WS, Tey HL: Nail psoriasis: a review. Am J Clin Dermatol 2012;13:375-388.
83.
Watanabe D, Kawamura C, Masuda Y, Akita Y, Tamada Y, Matsumoto Y: Successful treatment of toenail onychomycosis with photodynamic therapy. Arch Dermatol 2008;144:19-21.
84.
Piraccini BM, Rech G, Tosti A: Photodynamic therapy of onychomycosis caused by Trichophyton rubrum. J Am Acad Dermatol 2008;59:75-76.
85.
Sotiriou E, Koussidou-Eremonti T, Chaidemenos G, Apalla Z, Ioannides D: Photodynamic therapy for distal and lateral subungual toenail onychomycosis caused by Trichophyton rubrum: preliminary results of a single centre open trial. Acta Derm Venereol 2010;90:216-217.
86.
Robres P, Aspiroz C, Rezusta A, Gilaberteb Y: Usefulness of photodynamic therapy in the management of onychomycosis. Actas Dermosifiliogr 2015;106:795-805.
87.
Souza LW, Souza SV, Botelho AC: Distal and lateral toenail onychomycosis caused by Trichophyton rubrum: treatment with photodynamic therapy based on methylene blue dye. An Bras Dermatol 2014;89:184-186.
88.
Pasch MC: Nail psoriasis: a review of treatment options. Drugs 2016;76:675-705.
89.
Huang YC, Chou CL, Chiang YY: Efficacy of pulsed dye laser plus topical tazarotene versus topical tazarotene alone in psoriatic nail disease: a single-blind, intrapatient left-to-right controlled study. Lasers Surg Med 2013;45:102-107.
90.
Gold MH, Bradshaw VL, Boring MM, Bridges TM, Biron JA, Lewis TL: Treatment of sebaceous gland hyperplasia by photodynamic therapy with 5-aminolevulinic acid and a blue light source or intense pulsed light source. J Drugs Dermatol 2004;3:S6-S9.
91.
Simmons BJ, Griffith RD, Falto-Aizpurua LA, Bray FN, Nouri K: Light and laser therapies for the treatment of sebaceous gland hyperplasia a review of the literature. J Eur Acad Dermatol Venereol 2015;29:2080-2087.
92.
Kim SK, Do JE, Kang HY, Lee ES, Kim YC: Combination of topical 5-aminolevulinic acid-photodynamic therapy with carbon dioxide laser for sebaceous hyperplasia. J Am Acad Dermatol 2007;56:523-524.
93.
Alster TS, Tanzi EL: Photodynamic therapy with topical aminolevulinic acid and pulsed dye laser irradiation for sebaceous hyperplasia. J Drugs Dermatol 2003;2:501-504.
94.
Richey DF: Aminolevulinic acid photodynamic therapy for sebaceous gland hyperplasia. Dermatol Clin 2007;25:59-65.
95.
Otberg N, Kang H, Alzolibani AA, Shapiro J: Folliculitis decalvans. Dermatol Ther 2008;21:238-244.
96.
Wan MT, Lin JY: Current evidence and applications of photodynamic therapy in dermatology. Clin Cosmet Investig Dermatol 2014;7:145-163.
97.
Castaño-Suárez E, Romero-Maté A, Arias-Palomo D, Borbujo J: Photodynamic therapy for the treatment of folliculitis decalvans. Photodermatol Photoimmunol Photomed 2012;28:102-104.
98.
Miguel-Gomez L, Vano-Galvan S, Perez-Garcia B, Carrillo-Gijon R, Jaen-Olasolo P: Treatment of folliculitis decalvans with photodynamic therapy: results in 10 patients. J Am Acad Dermatol 2015;72:1085-1087.
99.
Burillo-Martinez S, Maroñas-Jimenez L, Palencia-Pérez SI, Vanaclocha-Sebastián F, López-Gómez S: Failure of photodynamic therapy (PDT) in 3 patients with folliculitis decalvans. J Am Acad Dermatol 2016;74:69-70.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.